Delving into the Latest Updates on Pharvaris Netherlands BV with Synapse

概览

疾病领域	数量

免疫系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

B2 receptor(缓激肽B2受体)	1

关联

1

项与 Pharvaris Netherlands BV 相关的药物

Deucrictibant

靶点

B2 receptor

作用机制

B2 receptor拮抗剂

在研机构

Pharvaris Netherlands BV

原研机构

Pharvaris Netherlands BV

在研适应症

遗传性血管性水肿 [+2]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

16

项与 Pharvaris Netherlands BV 相关的临床试验

NCT06669754 / Not yet recruiting临床3期

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

开始日期2024-12-01

申办/合作机构

Pharvaris Netherlands BV

CTIS2023-506305-18-01 / Recruiting

- PHA022121-C014

开始日期2024-09-19

申办/合作机构

Pharvaris Netherlands BV

CTIS2024-514713-35-00 / Not yet recruiting

- PHA022121-C017

开始日期2024-08-22

申办/合作机构